Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: A randomized trial

AIDS

Volumn 30, Issue 2, 2016, Pages 221-230

  Katlama, Christine ^a,b,c   Lambert Niclot, Sidonie ^a,b,c   Assoumou, Lambert ^b,c   Papagno, Laura ^a,b,d   Lecardonnel, Francois ^a   Zoorob, Rima ^b,d   Tambussi, Giuseppe ^e   Clotet, Bonaventura ^f   Youle, Mike ^g   Achenbach, Chad J ^h   Murphy, Robert L ^h   Calvez, Vincent ^a,b,c   Costagliola, Dominique ^b,c   Autran, Brigitte ^a,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d INSERM   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy intensification; HIV cure; HIV DNA; HIV eradication; immune modulation; interleukin 7; maraviroc; raltegravir

Indexed keywords

INTERLEUKIN 7; MARAVIROC; RALTEGRAVIR; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC DISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTENSION; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; STOP CODON; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIREMIA; VIRUS REACTIVATION; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VIRUS ACTIVATION; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DNA, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-7; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84952944336     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000894     Document Type: Article

References (34)

1. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis Off Publ Infect Dis Soc Am 2005; 41:1053-1056.
2. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard J-P, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS Lond Engl 2010; 24:1598-1601.
3. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
4. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. eLife 2014; 3:e03821.
5. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
6. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-2117.
7. Chun T-W, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
8. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cellto-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-98.
9. J Buzón M, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
10. Yukl SA, Shergill A, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T cell activation in multiple gut sites of HIVR adults on suppressive antiretroviral therapy. AIDS Lond Engl 2010; 24:2451-2460.
11. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
12. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-9408.
13. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76:13077-13082.
14. Levy Y, Lacabaratz C,Weiss L, Viard J-P, Goujard C, Lelièvre J-D, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009. doi:10.1172/JCI38052.
15. Wang F-X, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137.
16. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-6314.
17. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121:4321-4329.
18. Stopak KS, Chiu Y-L, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 2007; 282:3539-3546.
19. Achenbach CJ, Assoumou L, Deeks SG, Wilkin TJ, Berzins BI, Casazza J, et al. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIVspecific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. Lancet HIV 2015; 2:e82-e91.
20. Avettand-Fènoël V, Chaix M-L, Blanche S, Burgard M, Floch C, Toure K, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81:217-223.
21. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term nonprogressors. AIDS Lond Engl 2008; 22:1880-1882.
22. Descours B, Lambert-Niclot S, Mory B, Samri A, Charlotte F, Peytavin G, et al. Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIVinfected patients. J Acquir Immune Defic Syndr 2013; 62:255-259.
23. Häm-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS Lond Engl 2011; 25:341-344.
24. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother 2012; 67:2323-2326.
25. De Masson A, Kirilovsky A, Zoorob R, Avettand-Fenoel V, Morin V, Oudin A, et al. Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4R T cells from elite controllers. AIDS Lond Engl 2014. doi:10.1097/QAD.0000000000000295.
26. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
27. Fourati S, Flandre P, Calin R, Carcelain G, Soulie C, Lambert-Niclot S, et al. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother; 2013. doi:10.1093/jac/dkt428.
28. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9:e1003174.
29. Pogliaghi M, Lambert S, Assoumou L, Zoorob R, Papagno L. HIV reservoir changes in resting CD4 subsets in the IL7 plus ART intensification EraMune-01 study. 20th Conference on Retrovirus and Opportunistic Infections, Boston 2014, Abstract 424.
30. Markowitz M, Evering TH, Garmon D, Caskey M, La Mar M, Rodriguez K, et al. A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014; 66:140-147.
31. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
32. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004473.
33. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccines Immunother 2013; 9:993-1001.
34. Sogaard OS, Graversen ME, Leth S, Brinkmann CR, Kjær A-S, Olesen R, et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. International AIDS Conference 2014. Melbourne, Australia; 20-25 July 2014; TUAA0106LB.